Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Granules India Ltd. Share Price
Day's Range
Day's Range
Low
₹830.75
High
₹856.90
Price Summary
| Previous Close | ₹833.55 |
|---|---|
| Day's Range | ₹830.75 - ₹856.90 |
| Open | ₹846.00 |
| 52 Week Range | ₹432.60 - ₹910.00 |
| Volume | 8,70,853 |
| Market Cap | ₹0.02 |
| Previous Close | ₹833.65 |
|---|---|
| Day's Range | ₹831.90 - ₹856.00 |
| Open | ₹842.05 |
| 52 Week Range | ₹433.00 - ₹910.00 |
| Volume | 16,670 |
| Market Cap | ₹0.02 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 7,334.38 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.21 |
| Price/Earning (TTM) | 31.19 |
| TTM EPS (₹) | 26.73 |
| P/E Ratio | 25.87 |
| Book Value(₹) | 4.22 |
| PAT Margin (%) | 5.94 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 15.74 |
| Trade Value ( ₹ in Lacs) | 140.26 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.21 |
| Price/Earning (TTM) | 31.19 |
| TTM EPS (₹) | 26.73 |
| P/E Ratio | 25.87 |
| Book Value(₹) | 4.22 |
| PAT Margin (%) | 5.94 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 15.74 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 12101.06 | 44816.08 |
| Expenses | N/A | N/A |
| PBT | 1445.25 | 6601.66 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1126.36 | 5015.16 |
About Granules India Ltd.
| Founded | 1991 |
|---|---|
| Managing Director | Krishna Prasad Chigurupati |
| NSE Symbol | GRANULES |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,65,710.92 | 1,941.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,92,375.79 | 7,240.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,88,654.85 | 4,959.80 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,26,592.33 | 8,816.50 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,13,978.90 | 1,409.95 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,10,613.20 | 1,108.90 | 835.50 - 835.50 |
| Lupin Ltd. | 1,08,339.52 | 2,374.00 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,05,259.52 | 1,078.90 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,03,472.01 | 2,509.65 | 1,909.70 - 1,909.70 |
| Lenskart Solutions Ltd. | 96,638.09 | 557.45 | 0.00 - 0.00 |
No Records Found
Latest News
Granules India informs about audio recording of conference call
Pursuant to regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Granules India has informed that the audio recording of the earnings conference call of the Company for the Q1 of FY27 has been uploaded on the website of the Company at the below-mentioned link: https://granulesindia.com/investors/investor-resources/earnings-call-recording/.
The above information is a part of company’s filings submitted to BSE.
Granules India informs about updates
Granules India informs about outcome of board meeting
Granules India submits board meeting intimation
Granules India informs about press release
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Granules India Ltd. is ₹833.55 as of 2026-07-24.
The market capitalisation of Granules India Ltd. is ₹20,657.59 as of 2026-07-24.
The 1-year return of Granules India Ltd. is 364.45% as of 2026-07-24.
The P/E ratio of Granules India Ltd. is 25.87 as of 2026-07-26.
The 52-week high and low of Granules India Ltd. are ₹910.00 and ₹432.60, respectively, as of 2026-07-24.
People Also Ask
Granules India Ltd. engages with global pharmaceutical companies through contract manufacturing and long-term supply arrangements. The company supplies pharmaceutical ingredients and formulations at scale, supporting partners in their manufacturing and supply chain requirements.
Granules India Ltd. focuses on high-volume pharmaceutical products, including Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Its portfolio includes widely used drugs such as paracetamol and ibuprofen.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
